Compare Ascendis Pharma A/S (ASND) vs Duke Energy Corp (DUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Duke Energy Corp — how do they compare? Ascendis Pharma A/S trades at $263.79 (market cap $17.74B), while Duke Energy Corp trades at $126.04 (market cap $97.82B). The key difference: Duke Energy Corp is far larger — about 5.5× Ascendis Pharma A/S's market cap, and Duke Energy Corp pays a 3.39% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DUK | |
|---|---|---|
Market Cap | $17.74B | $97.82B |
Sector | Health | Utilities |
52-Week High | $277.18 | $133.46 |
52-Week Low | $163.32 | $113.99 |
Enterprise Value | $18.11B | $187.87B |
Dividend Yield | — | 3.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Duke Energy (DUK) trades at $125.48, up 0.18% on the day, with a bearish technical signal despite recent earnings beats. The stock shows stable revenue growth to $32.24B in 2025 and a net income margin of 15.49%, supported by a dividend yield from its recent $1.07 payout. Analyst consensus is mixed with 40.6% buy ratings and a $137.67 price target, indicating potential upside. Technical resistance sits at $127, with support at $124.
DUK offers defensive appeal with consistent profitability and dividend reliability, but faces headwinds from high debt levels (46.17% debt-to-asset ratio) and capital-intensive infrastructure demands. The stock's neutral RSI and bearish moving averages suggest near-term consolidation, while long-term growth hinges on execution in a regulated utility environment amid rising data center energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →
